HROW Harrow, Inc. - Common Stock
$39,50
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 10, 2026
Rango 52S
$29–$55
42% of range
Calificación del Analista
BUY
14 analysts
Precio Objetivo
$68
+71% upside
P/E (TTM)
-282.1
ROE
-8.4%
Margen de Beneficio Neto
-1.9%
Acerca de Harrow, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Leer más
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
HROW Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$39.50
Capitalización Bursátil
$1.47B
P/E (TTM)
-282.1
BPA (TTM)
$-0.14
Ingresos (TTM)
$272M
Rendimiento div.
—
ROE
-8.4%
Deuda/Capital
—
Rango 52S
$29 – $55
HROW Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$272M
2016-12-31
→
2025-12-31
BPA
$-0.14
2017-12-31
→
2025-12-31
Flujo de caja libre
$43M
2016-12-31
→
2025-12-31
Márgenes
-1.9%
2016-12-31
→
2025-12-31
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
HROW
Mediana de Pares
P/E (TTM)
-282.1
31.7
P/S (TTM) (P/V (TTM))
5.4
5.1
P/B (P/C)
28.0
4.8
Price / FCF (Precio / FCF)
34.2
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
HROW
Mediana de Pares
Gross Margin (Margen Bruto)
75.0%
74.1%
Operating Margin (Margen Operativo)
11.2%
—
Net Profit Margin (Margen de Beneficio Neto)
-1.9%
-0.88%
ROA
-1.3%
-2.9%
ROE
-8.4%
-6.8%
ROIC
218.6%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
HROW
Mediana de Pares
Current Ratio (Ratio corriente)
2.2
4.7
Quick Ratio (Ratio Rápido)
1.9
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
HROW
Mediana de Pares
Revenue YoY (Ingresos interanuales)
36.4%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
45.4%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
41.0%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
HROW
Mediana de Pares
HROW Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
14 analistas
- Compra fuerte 5 35,7%
- Compra 8 57,1%
- Mantener 1 7,1%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
8 analistas · 2026-08-18
Mediana
$61.50
Media
$67.50
← Por Debajo de Todos los Objetivos
$39.50
Mín
$59.00
Máx
$88.00
Objetivo mediano
$61.50
+55,7%
Objetivo medio
$67.50
+70,9%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.18%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.34 | $-0.18 | -0.16% |
| 31 de marzo de 2026 | $-0.74 | $-0.41 | -0.33% |
| 31 de diciembre de 2025 | $0.17 | $0.38 | -0.21% |
| 30 de septiembre de 2025 | $0.22 | $0.27 | -0.05% |
| 30 de junio de 2025 | $0.13 | $0.01 | 0.12% |
| 31 de marzo de 2025 | $-0.50 | $-0.05 | -0.45% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| ETON | $457M | — | 104.9% | -5.8% | -18.4% | 53.5% |
| AVLN | — | — | — | — | — | — |
| MAZE | $2.04B | -13.6 | — | — | -598.9% | — |
| INVA | — | 6.1 | 14.7% | — | — | — |
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| XERS | $1.30B | — | 43.7% | 0.19% | -19.7% | — |
| PAHC | — | 21.5 | 27.4% | 3.7% | 17.8% | 30.9% |
| SPTX | — | — | — | — | — | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Balance general 27
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Flujo de Efectivo 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Estado de resultados 17
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | -73,001,737 | 37,145,440 | 36,790,306 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | -76,794,851 | 38,875,005 | 38,853,855 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Balance general 27
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Flujo de Efectivo 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Rentabilidad 8
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $250M | $227M | · | $232M | $210M | $181M | · | $167M | $151M | $128M | · | $117M | $106M | $94M | · | $87M | |
| Net Income TTM | $-39M | $-39M | · | $-16M | $-23M | $-42M | · | $-29M | $-29M | $-29M | · | $-22M | $-24M | $-22M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -40.8 | -32.6 | · | -104.7 | -45.6 | -22.5 | · | -55.5 | -25.2 | -15.2 | · | -19.7 | -22.9 | -27.1 | · | -13.9 | |
| P/S | 6.4 | 5.8 | · | 7.7 | 5.3 | 5.3 | · | 9.6 | 4.9 | 3.6 | · | 4.3 | 5.5 | 6.7 | · | 3.8 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| P / FCF | · | -143.1 | · | · | · | 48.6 | · | · | · | -99.2 | · | · | · | -73.0 | · | · | |
| EV / EBITDA | · | · | · | 129.6 | 106.5 | -90.7 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | 50.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | 8.4 | 6.0 | 5.5 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.5% | -3.1% | · | -0.95% | -2.2% | -4.4% | · | -1.8% | -4.0% | -6.6% | · | -5.1% | -4.4% | -3.7% | · | -7.2% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $272M | $200M | $130M | $89M | $72M |
| Margen Bruto % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Margen Operativo % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Beneficio neto | $-5M | $-17M | $-24M | $-14M | $-18M |
| EPS Diluido | $-0.14 | $-0.49 | $-0.75 | $-0.51 | — |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Ratio Rápido | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $43M | $-24M | $2M | $-892.0K | $3M |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 244 declarantes · $773.6M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 48 (+8 vs trimestre anterior) | 34 (+4 vs trimestre anterior) | 74 (+1 vs trimestre anterior) | 67 (-4 vs trimestre anterior) | +1.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Opaleye Management Inc. | $101 928 000 | 2 400 000 | 13,18% | Acciones |
| Private Capital Management, LLC | $67 899 762 | 1 598 770 | 8,78% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $60 188 994 | 1 417 212 | 7,78% | Acciones |
| Deep Track Capital, LP | $41 153 430 | 969 000 | 5,32% | Acciones |
| STATE STREET CORP | $39 917 043 | 939 888 | 5,16% | Acciones |
| BAMCO INC /NY/ | $34 373 094 | 809 350 | 4,44% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $33 342 270 | 784 905 | 4,31% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31 550 963 | 742 900 | 4,08% | Opción de compra |
| DIMENSIONAL FUND ADVISORS LP | $26 788 590 | 630 765 | 3,46% | Acciones |
| Divisadero Street Capital Management, LP | $18 650 913 | 439 155 | 2,41% | Acciones |
| CITADEL ADVISORS LLC | $16 622 758 | 391 400 | 2,15% | Opción de compra |
| RICE HALL JAMES & ASSOCIATES, LLC | $16 459 036 | 387 545 | 2,13% | Acciones |
| Schonfeld Strategic Advisors LLC | $13 574 473 | 319 625 | 1,75% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13 531 367 | 318 610 | 1,75% | Acciones |
| MARSHALL WACE, LLP | $12 157 037 | 286 250 | 1,57% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11 623 869 | 273 696 | 1,50% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $9 998 202 | 235 418 | 1,29% | Acciones |
| CITADEL ADVISORS LLC | $9 895 510 | 233 000 | 1,28% | Opción de venta |
| Westside Investment Management, Inc. | $9 473 007 | 223 051 | 1,22% | Acciones |
| FirstWave Capital Management LLC | $9 002 833 | 211 981 | 1,16% | Acciones |
| Blackhawk Capital Partners, LLC | $8 631 645 | 203 241 | 1,12% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8 074 227 | 190 116 | 1,04% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7 827 221 | 184 300 | 1,01% | Opción de venta |
| JANE STREET GROUP, LLC | $7 772 010 | 183 000 | 1,00% | Opción de compra |
| ROYCE & ASSOCIATES LP | $6 565 310 | 154 587 | 0,85% | Acciones |
| Ikarian Capital, LLC | $5 766 364 | 135 775 | 0,75% | Acciones |
| Advantage Alpha Capital Partners LP | $5 374 624 | 111 553 | 0,69% | Acciones |
| Diametric Capital, LP | $4 965 082 | 116 908 | 0,64% | Acciones |
| WOODMONT INVESTMENT COUNSEL LLC | $4 748 571 | 111 810 | 0,61% | Acciones |
| FIRST TRUST ADVISORS LP | $4 260 378 | 100 315 | 0,55% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $4 146 219 | 97 627 | 0,54% | Acciones |
| 12th Street Asset Management Company, LLC | $3 882 140 | 91 409 | 0,50% | Acciones |
| Lumbard & Kellner, LLC | $3 835 975 | 90 322 | 0,50% | Acciones |
| Steward Partners Investment Advisory, LLC | $3 832 960 | 90 251 | 0,50% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $3 575 210 | 84 182 | 0,46% | Acciones |
| EQUITABLE TRUST CO | $3 371 184 | 79 378 | 0,44% | Acciones |
| BANK OF AMERICA CORP /DE/ | $3 138 533 | 73 900 | 0,41% | Acciones |
| Squarepoint Ops LLC | $3 126 726 | 73 622 | 0,40% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 004 668 | 70 748 | 0,39% | Acciones |
| Swiss National Bank | $2 696 845 | 63 500 | 0,35% | Acciones |
| CITADEL ADVISORS LLC | $2 533 888 | 59 663 | 0,33% | Acciones |
| Jefferson Bridge Capital, LLC | $2 427 925 | 57 168 | 0,31% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $2 395 903 | 56 414 | 0,31% | Acciones |
| Militia Capital Partners, LP | $2 303 000 | 47 000 | 0,30% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $2 288 921 | 53 895 | 0,30% | Acciones |
| GROUP ONE TRADING LLC | $2 085 914 | 49 115 | 0,27% | Acciones |
| LJI Wealth Management, LLC | $2 021 572 | 47 600 | 0,26% | Acciones |
| JANE STREET GROUP, LLC | $2 000 337 | 47 100 | 0,26% | Opción de venta |
| RENAISSANCE TECHNOLOGIES LLC | $1 894 884 | 44 617 | 0,24% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1 863 796 | 43 885 | 0,24% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $1 841 542 | 43 361 | 0,24% | Acciones |
| RHUMBLINE ADVISERS | $1 739 772 | 40 965 | 0,22% | Acciones |
| BARD ASSOCIATES INC | $1 716 171 | 40 409 | 0,22% | Acciones |
| BLAIR WILLIAM & CO/IL | $1 693 704 | 39 880 | 0,22% | Acciones |
| LPL Financial LLC | $1 547 267 | 36 432 | 0,20% | Acciones |
| Campbell & CO Investment Adviser LLC | $1 541 066 | 36 286 | 0,20% | Acciones |
| D.A. DAVIDSON & CO. | $1 471 586 | 34 650 | 0,19% | Acciones |
| BOOTHBAY FUND MANAGEMENT, LLC | $1 417 351 | 33 373 | 0,18% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $1 390 549 | 39 437 | 0,18% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1 375 810 | 39 019 | 0,18% | Acciones |
| STANSBERRY ASSET MANAGEMENT, LLC | $1 360 399 | 32 032 | 0,18% | Acciones |
| GOLDMAN SACHS GROUP INC | $1 330 713 | 31 333 | 0,17% | Acciones |
| Brookstone Capital Management | $1 323 068 | 31 153 | 0,17% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $1 273 208 | 29 979 | 0,16% | Acciones |
| GREAT LAKES ADVISORS, LLC | $1 145 119 | 26 963 | 0,15% | Acciones |
| KORNITZER CAPITAL MANAGEMENT INC /KS | $1 117 556 | 26 314 | 0,14% | Acciones |
| BlackRock, Inc. | $1 115 899 | 26 275 | 0,14% | Acciones |
| Crawford Fund Management, LLC | $1 113 563 | 26 220 | 0,14% | Acciones |
| Bank of New York Mellon Corp | $1 109 571 | 26 126 | 0,14% | Acciones |
| OSAIC HOLDINGS, INC. | $1 066 373 | 25 109 | 0,14% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $1 063 406 | 25 039 | 0,14% | Acciones |
| ExodusPoint Capital Management, LP | $1 029 600 | 24 243 | 0,13% | Acciones |
| Bleakley Financial Group, LLC | $1 022 125 | 24 067 | 0,13% | Acciones |
| Birchview Capital, LP | $1 019 280 | 24 000 | 0,13% | Acciones |
| XTX Topco Ltd | $983 053 | 23 147 | 0,13% | Acciones |
| Focus Partners Wealth | $979 826 | 23 071 | 0,13% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $954 556 | 22 476 | 0,12% | Acciones |
| COMMERCE BANK | $952 602 | 22 430 | 0,12% | Acciones |
| Squarepoint Ops LLC | $925 846 | 21 800 | 0,12% | Opción de venta |
| VANGUARD ASSET MANAGEMENT, Ltd | $904 399 | 21 295 | 0,12% | Acciones |
| IMC-Chicago, LLC | $886 646 | 20 877 | 0,11% | Acciones |
| FineMark National Bank & Trust | $854 070 | 17 430 | 0,11% | Acciones |
| Sonora Investment Management Group, LLC | $826 191 | 17 148 | 0,11% | Acciones |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $806 930 | 19 000 | 0,10% | Acciones |
| MetLife Investment Management, LLC | $803 023 | 18 908 | 0,10% | Acciones |
| Private Capital Management, LLC | $743 225 | 17 500 | 0,10% | Opción de compra |
| Round Rock Advisors LLC | $742 418 | 17 481 | 0,10% | Acciones |
| MML INVESTORS SERVICES, LLC | $707 805 | 16 666 | 0,09% | Acciones |
| Lido Advisors, LLC | $700 288 | 16 489 | 0,09% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $692 091 | 16 296 | 0,09% | Acciones |
| Atria Investments, Inc | $683 215 | 16 087 | 0,09% | Acciones |
| UBS Group AG | $672 640 | 15 838 | 0,09% | Acciones |
| BARCLAYS PLC | $672 215 | 15 828 | 0,09% | Acciones |
| SIMPLEX TRADING, LLC | $651 872 | 15 349 | 0,08% | Acciones |
| ARISTEIA CAPITAL, L.L.C. | $651 702 | 15 345 | 0,08% | Acciones |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $633 270 | 14 911 | 0,08% | Acciones |
| VANGUARD GROUP INC | $617 155 | 12 595 | 0,08% | Acciones |
| Grandeur Peak Global Advisors, LLC | $609 572 | 14 353 | 0,08% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $600 441 | 14 138 | 0,08% | Acciones |
| Walleye Partners, LLC | $572 369 | 13 477 | 0,07% | Acciones |
Informantes de la empresa 20 insiders · 5 directivos · 11 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | Chief Executive Officer | 10 de febrero de 2014 A | 1 419 835 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 de junio de 2009 A | 1 954 125 | 0 | 0 | $0 |
| Andrew Boll | VP, Accounting and Reporting | 10 de febrero de 2014 A | — | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1 de abril de 2013 A | — | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 de febrero de 2010 A | — | 0 | 0 | $0 |
| Perry J. Sternberg | Consejero | 18 de junio de 2026 A | — | 0 | 0 | $0 |
| Adrienne L Graves | Consejero | 18 de junio de 2026 A | — | 0 | 0 | $0 |
| Lauren P Silvernail | Consejero | 18 de junio de 2026 A | — | 0 | 0 | $0 |
| Peter C Kenny | Consejero | 2 de octubre de 2013 A | 8 947 | 0 | 0 | $0 |
| Robert J Kammer | Consejero | 28 de junio de 2013 A | 931 689 | 0 | 0 | $0 |
| August Shelby Bassani | Consejero | 27 de junio de 2013 A | 6 865 | 0 | 0 | $0 |
| Paul Finnegan | Consejero | 27 de junio de 2013 A | 6 865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Consejero | 27 de junio de 2013 A | 45 927 | 0 | 0 | $0 |
| Stephen G Austin | Consejero | 27 de junio de 2013 A | 6 865 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Propietario del 10% | 12 de julio de 2012 J | 0 | 0 | 0 | $0 |
| Amir Shojaei | — | 14 de agosto de 2026 M | 0 | 0 | 1 | $-450 000 |
| John N Bonfiglio | — | 20 de octubre de 2010 A | 50 000 | 0 | 0 | $0 |
| John T Lomoro | — | 19 de junio de 2009 A | — | 0 | 0 | $0 |
| Lynn C Swann | — | 21 de noviembre de 2008 A | 25 000 | 0 | 0 | $0 |
| Anthony S Thornley | — | 21 de noviembre de 2008 A | 60 900 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 5 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Mark L. Baum ×3 presentaciones | 7 de abril de 2025 | 10,69% | Enmienda | — | SEC |
| 27 de abril de 2021 | — | Presentación inicial | — | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 presentaciones | 30 de agosto de 2016 | — | Presentación inicial | — | SEC |
| Dr. Robert J. Kammer ×2 presentaciones | 16 de agosto de 2013 | — | Presentación inicial | — | SEC |
| DermaStar International, LLC ×7 presentaciones | 10 de agosto de 2012 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 46 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,47% | 4 670 NS | 30 de abril de 2026 | N-PORT |
| IWC · iShares Trust | 0,29% | 109 900 SH | 8 de agosto de 2026 | Diario |
| IHE · iShares Trust | 0,29% | 118 464 SH | 8 de agosto de 2026 | Diario |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,26% | 66 235 NS | 30 de abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,10% | 2 031 SH | 8 de agosto de 2026 | Diario |
| GSSC · Goldman Sachs ETF Trust | 0,10% | 28 159 NS | 31 de mayo de 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 48 827 NS | 30 de abril de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34 722 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,08% | 291 642 SH | 8 de agosto de 2026 | Diario |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,07% | 19 636 NS | 30 de abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,07% | 1 370 NS | 31 de mayo de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 10 343 NS | 30 de abril de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 6 175 NS | 30 de abril de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 2 997 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,04% | 824 976 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186 298 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,04% | 13 694 NS | 30 de abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 123 278 NS | 30 de abril de 2026 | N-PORT |
| ISCG · iShares Trust | 0,03% | 8 711 SH | 8 de agosto de 2026 | Diario |
| SMLF · iShares Trust | 0,03% | 33 778 SH | 8 de agosto de 2026 | Diario |
| ITWO · ProShares Trust | 0,03% | 1 486 NS | 31 de mayo de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 158 672 NS | 31 de mayo de 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,02% | 18 041 NS | 31 de mayo de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 14 677 NS | 30 de abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383 679 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,02% | 94 953 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,02% | 1 222 SH | 8 de agosto de 2026 | Diario |
| UWM · ProShares Trust | 0,02% | 1 162 NS | 31 de mayo de 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2 264 SH | 8 de agosto de 2026 | Diario |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,01% | 860 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 1 174 NS | 31 de mayo de 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 30 de abril de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 1 223 NS | 31 de mayo de 2026 | N-PORT |
| EBI · RBB Fund Trust | 0,01% | 984 NS | 31 de mayo de 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,00% | 18 264 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 29 NS | 31 de mayo de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 50 366 NS | 30 de abril de 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 11 315 NS | 31 de mayo de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 8 641 NS | 30 de abril de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 856 NS | 30 de abril de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11 363 NS | 30 de abril de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45 405 SH | 8 de agosto de 2026 | Diario |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 19 602 NS | 31 de mayo de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 6 962 SH | 8 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 001 445 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 637 SH | 8 de agosto de 2026 | Diario |